Using patients' own cells to treat osteoarthritis
Official title: Adipose-Derived Biocellular Regenerative Therapy in Treatment of Osteoarthritis (OA) and Associated Connective Tissue Degeneration and Pain
Run by Healeon Medical Inc · NCT04238143 · Data updated 2026-11-12
This study is testing whether using patients' own stem cells and platelet-rich plasma can help treat osteoarthritis better than traditional methods.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Healeon Medical Inc Industry-sponsored |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 2 sites (Valencia, California and 1 other locations) |
| Status | Recruiting |
| Started | January 10, 2020 |
| Main results expected | September 30, 2026 |
| Study ends | September 30, 2027 |
| Registry record updated | October 1, 2024 |
| Trial ID | NCT04238143 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals with documented osteoarthritic changes in joints such as the knee, hip, or shoulder, who are able to tolerate the procedures.
✕Probably not a fit
Patients with systemic disorders, active cancer, or those who are pregnant may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of autologous stem/stromal cells combined with high-dose platelet-rich plasma (HD-PRP) to treat osteoarthritis (OA) through minimally invasive methods. It aims to address the limitations of traditional surgical interventions and medical management by employing biocellular and cellular therapies. Participants will undergo various treatment approaches, including guided biocellular therapy and systemic deployment of cellular stromal vascular fraction (cSVF), with their progress tracked over time. The study will document baseline findings and evaluate the safety and effectiveness of these innovative treatments.
Why it matters
Potential benefit: If successful, this approach could provide a long-term, minimally invasive treatment option for patients suffering from osteoarthritis.
How similar studies have gone: Other studies have shown promise with similar biocellular approaches, but this specific methodology is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Documented osteoarthritic inflammatory and/or degenerative changes in the joint or connective tissues of the knee, hip, shoulder, Achilles tendon, Sacroiliac Joint, wrist/hand, foot/ankle, or Plantar Fasciitis (PR); * No systemic disorders which, in opinion of principal investigator, would disqualify from safely being able to undergo the determined procedures; * Have the ability to understand and accept all items in Informed Consent Document; * Have adequate perivascular and extracellular matrix donor tissues available; * Mature enough to tolerate determined procedures and follow up instructions and complete post-treatment tracking responsibilities Exclusion Criteria: * Systemic or psychological impairment which would preclude patient tolerance and understanding nature and extent of procedures and follow up tracking; * Known active cancer, chemotherapy, or radiation therapy; * Pregnancy; * Active infections which would increase risk of patient to undergo treatment; * High dose steroid users, or recipients of corticosteroids with a six month period before treatment date; * Medication or Opiate addition, or in active treatment for drug rehabilitation; * History of documented severe traumatic brain injuries; * In the opinion of the principal investigator/provider, the patient's condition or medical issues which would not allow the individual to fully accomplish or complete the study requirements
Where it's running
-
Hemwall Center for Orthopedic Regenerative Medicine
Valencia, California, United States Recruiting -
Regenevita LLC
Stevensville, Montana, United States Not yet recruiting
Study contacts
- Study coordinator: Donna Alderman, DO
- Email: hemwallcenter@prolotherapy.com
- Phone: 1 661 295 1110
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Arthrosamid versus steroid injections for managing knee osteoarthritis.
This trial will test whether a single Arthrosamid hydrogel injection works better than a standard steroid plus local anesthetic injection for adults with symptomatic knee osteoarthritis.
-
Choose to Move Replacement Ready for people waiting for hip or knee replacement
This project will test whether the Choose to Move Replacement Ready program helps older adults on hip or knee replacement waitlists increase physical activity, improve mobility, and support psychosocial health.
-
Evaluating OA-SYS for knee osteoarthritis treatment
This study is testing a new treatment called OA-SYS using adult stem cells to see if it can help people with moderate to severe knee osteoarthritis feel better and improve their knee function.
-
Targeting abnormal blood flow to treat chronic joint pain in veterans
This study is testing if treating abnormal blood flow in the joints can help veterans with chronic pain and osteoarthritis feel better.
-
Low-impact exercise program for joint pain relief
This study is testing if joining low-impact exercise classes can help people with knee, hip, and ankle pain from osteoarthritis feel better and move easier.
-
Autologous adipose-derived stem cell injections for knee osteoarthritis
We’re testing whether injecting a patient’s own fat-derived stem cells into the knee can help people with knee OA feel less pain and move better, compared with a standard hyaluronic acid treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.